Vandetanib (RET, VEGFR2/3, EGFR) and cabozantinib (brand name: Cometriq) are multitargeted KIs, approved in 2011 and 2012, respectively, based on data from randomized, placebo-controlled phase 3 trials for unresectable or metastatic MTC. This evidence concerns the gene RET and medullary thyroid gland carcinoma.